Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Instil Bio, Inc. (NQ:TIL)

33.81 -0.59 (-1.72%)
Streaming Delayed Price Updated: 10:25 AM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Instil Bio, Inc.

< Previous 1 2 3 4 5 Next >
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,... 
Via Talk Markets
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
From Instil Bio
Via GlobeNewswire
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023. 
Via InvestorPlace
Instil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal Cancers
Via Benzinga
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Strategic Update
From Instil Bio
Via GlobeNewswire
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023. 
Via InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the third quarter of 2023. 
Via InvestorPlace
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells 
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Via Benzinga
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
From Instil Bio
Via GlobeNewswire
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
NASDAQ:TIL Shareholder Notice: Investigation over Potential Wrongdoing at Instil Bio, Inc.
San Diego, CA -- (SBWIRE) -- 02/10/2023 -- Certain directors of Instil Bio, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
From Instil Bio
Via GlobeNewswire
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback